BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol 2021:S0168-8278(21)01964-4. [PMID: 34380057 DOI: 10.1016/j.jhep.2021.07.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Kim D, Ahmed A. Reply to: "NAFLD vs. MAFLD - It is not the name but the disease that decides the outcome in fatty liver". J Hepatol 2021:S0168-8278(21)02164-4. [PMID: 34748894 DOI: 10.1016/j.jhep.2021.10.023] [Reference Citation Analysis]
2 Lee C. Metabolic dysfunction-associated fatty liver disease — How relevant is this to primary care physicians and diabetologists? Primary Care Diabetes 2022. [DOI: 10.1016/j.pcd.2022.01.005] [Reference Citation Analysis]
3 Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Int J Mol Sci 2021;22:11629. [PMID: 34769060 DOI: 10.3390/ijms222111629] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Vitale A, Svegliati-Baroni G, Ortolani A, Cucco M, Dalla Riva GV, Giannini EG, Piscaglia F, Rapaccini G, Di Marco M, Caturelli E, Zoli M, Sacco R, Cabibbo G, Marra F, Mega A, Morisco F, Gasbarrini A, Foschi FG, Missale G, Masotto A, Nardone G, Raimondo G, Azzaroli F, Vidili G, Oliveri F, Pelizzaro F, Ramirez Morales R, Cillo U, Trevisani F, Miele L, Marchesini G, Farinati F; Italian Liver Cancer (ITA.LI.CA) group. Epidemiological trends and trajectories of MAFLD-associated hepatocellular carcinoma 2002-2033: the ITA.LI.CA database. Gut 2021:gutjnl-2021-324915. [PMID: 34933916 DOI: 10.1136/gutjnl-2021-324915] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
5 Schnurr TM, Katz SF, Justesen JM, O'Sullivan JW, Saliba-Gustafsson P, Assimes TL, Carcamo-Orive I, Ahmed A, Ashley EA, Hansen T, Knowles JW. Interactions of physical activity, muscular fitness, adiposity, and genetic risk for NAFLD. Hepatol Commun 2022. [PMID: 35293152 DOI: 10.1002/hep4.1932] [Reference Citation Analysis]
6 Xie J, Lu L, Chen Y, Xu L, Xu C. A simpler definition of MAFLD better predicts long-term all-cause mortality in American adults. J Hepatol 2022:S0168-8278(22)00028-9. [PMID: 35121077 DOI: 10.1016/j.jhep.2022.01.015] [Reference Citation Analysis]
7 van Kleef LA, de Knegt RJ. The transition from NAFLD to MAFLD: One size still does not fit all-Time for a tailored approach? Hepatology 2022. [PMID: 35503710 DOI: 10.1002/hep.32552] [Reference Citation Analysis]
8 Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-peralta F. Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. JCM 2022;11:968. [DOI: 10.3390/jcm11040968] [Reference Citation Analysis]
9 Noda T, Kamiya K, Hamazaki N, Nozaki K, Ichikawa T, Yamashita M, Uchida S, Maekawa E, Terada T, Reed JL, Yamaoka-tojo M, Matsunaga A, Ako J. The Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease and Its Association with Physical Function and Prognosis in Patients with Acute Coronary Syndrome. JCM 2022;11:1847. [DOI: 10.3390/jcm11071847] [Reference Citation Analysis]
10 Fouad Y, Méndez-Sánchez N, Zheng MH. One Not Like the Other: The weakness of the blood sugar-MAFLD analogy. J Hepatol 2021:S0168-8278(21)02117-6. [PMID: 34678406 DOI: 10.1016/j.jhep.2021.10.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Xu W, Zhou F, Zhu Q, Bai M, Luo T, Zhou L, Deng R. Calycosin-7-O-β-D-glucoside attenuates palmitate-induced lipid accumulation in hepatocytes through AMPK activation. Eur J Pharmacol 2022;:174988. [PMID: 35490724 DOI: 10.1016/j.ejphar.2022.174988] [Reference Citation Analysis]
12 Younossi ZM, Paik JM, Al Shabeeb R, Golabi P, Younossi I, Henry L. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology 2022. [PMID: 35363908 DOI: 10.1002/hep.32499] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
13 Chen Y, Yang C, Chung C, Ho C, Chen W, Chien W. The association between metabolic risk factors, nonalcoholic fatty liver disease, and the incidence of liver cancer: a nationwide population-based cohort study. Hepatol Int. [DOI: 10.1007/s12072-021-10281-9] [Reference Citation Analysis]
14 Xie Z, Li H, Tan W, Yang L, Ma X, Li W, Wang Q, Shang C, Chen Y. Association of Serum Vitamin C With NAFLD and MAFLD Among Adults in the United States. Front Nutr 2022;8:795391. [DOI: 10.3389/fnut.2021.795391] [Reference Citation Analysis]
15 Zhu C, Ma H, Huang D, Li G, Gao J, Cai M, You H, Bu L, Qu S. J-Shaped Relationship Between Serum Prolactin and Metabolic-Associated Fatty Liver Disease in Female Patients With Type 2 Diabetes. Front Endocrinol 2022;13:815995. [DOI: 10.3389/fendo.2022.815995] [Reference Citation Analysis]
16 Ayada I, van Kleef LA, Alferink LJM, Li P, de Knegt RJ, Pan Q. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int 2021. [PMID: 34953098 DOI: 10.1111/liv.15139] [Reference Citation Analysis]
17 Ismaiel A, Spinu M, Budisan L, Leucuta DC, Popa SL, Chis BA, Berindan-Neagoe I, Olinic DM, Dumitrascu DL. Relationship between Adipokines and Cardiovascular Ultrasound Parameters in Metabolic-Dysfunction-Associated Fatty Liver Disease. J Clin Med 2021;10:5194. [PMID: 34768714 DOI: 10.3390/jcm10215194] [Reference Citation Analysis]
18 De A, Ahmad N, Mehta M, Singh P, Duseja A. NAFLD Vs MAFLD - It is not the name but the disease that decides the outcome in fatty liver. J Hepatol 2021:S0168-8278(21)02032-8. [PMID: 34530064 DOI: 10.1016/j.jhep.2021.09.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Sumida Y. Renaming from nonalcoholic fatty liver disease to metabolism dysfunction associated fatty liver disease: Pros and cons. Hepatol Res 2022;52:415-6. [PMID: 35591814 DOI: 10.1111/hepr.13762] [Reference Citation Analysis]
20 Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;15:1295-307. [PMID: 34624198 DOI: 10.1080/17474124.2021.1991792] [Reference Citation Analysis]
21 Wong VW, Lazarus JV. Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change. J Hepatol 2021:S0168-8278(21)02015-8. [PMID: 34464658 DOI: 10.1016/j.jhep.2021.08.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Yang C, He Q, Chen Z, Qin J, Lei F, Liu Y, Liu W, Chen M, Sun T, Zhu Q, Wu Y, Zhuo M, Cai J, Mao W, Li H. A Bidirectional Relationship Between Hyperuricemia and Metabolic Dysfunction-Associated Fatty Liver Disease. Front Endocrinol 2022;13:821689. [DOI: 10.3389/fendo.2022.821689] [Reference Citation Analysis]
23 Jiang M, Sun J, Zou H, Li M, Su Z, Sun W, Kong X. Prognostic Role of Neutrophil to High-Density Lipoprotein Cholesterol Ratio for All-Cause and Cardiovascular Mortality in the General Population. Front Cardiovasc Med 2022;9:807339. [PMID: 35211525 DOI: 10.3389/fcvm.2022.807339] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Spiers J, Brindley JH, Li W, Alazawi W. What’s new in non-alcoholic fatty liver disease? Frontline Gastroenterol. [DOI: 10.1136/flgastro-2022-102122] [Reference Citation Analysis]
25 Lee SM, Jung YM, Choi ES, Kwak SH, Koo JN, Oh IH, Kim BJ, Kim SM, Kim SY, Kim GM, Joo SK, Koo BK, Shin S, Norwitz ER, Park CW, Jun JK, Kim W, Park JS. Metabolic Dysfunction-Associated Fatty Liver Disease and Subsequent Development of Adverse Pregnancy Outcomes. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01219-2. [PMID: 34798335 DOI: 10.1016/j.cgh.2021.11.007] [Reference Citation Analysis]
26 Zhu C, Huang D, Ma H, Qian C, You H, Bu L, Qu S. High-Sensitive CRP Correlates With the Severity of Liver Steatosis and Fibrosis in Obese Patients With Metabolic Dysfunction Associated Fatty Liver Disease. Front Endocrinol 2022;13:848937. [DOI: 10.3389/fendo.2022.848937] [Reference Citation Analysis]
27 Quek J, Ng CH, Tang ASP, Chew N, Chan M, Khoo CM, Wei CP, Chin YH, Tay P, Lim G, Tan DJH, Lim WH, Chan KE, Teng M, Tan E, Tamaki N, Huang DQ, Siddiqui MS, Young DY, Noureddin M, Muthiah MD. Metabolic Associated Fatty Liver Disease (MAFLD) Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12,620,736 Individuals. Endocr Pract 2022:S1530-891X(22)00102-1. [PMID: 35364328 DOI: 10.1016/j.eprac.2022.03.016] [Reference Citation Analysis]
28 Tsutsumi T, Kawaguchi T, Nakano D, Torimura T. Atherosclerotic cardiovascular disease in non-metabolic nonalcoholic fatty liver disease. Hepatol Res 2022;52:317-9. [PMID: 35229393 DOI: 10.1111/hepr.13738] [Reference Citation Analysis]
29 Yoon EL, Jun DW. Waiting for Multi-Stakeholders'Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature. Gut Liver 2022;16:319-20. [PMID: 35551103 DOI: 10.5009/gnl220183] [Reference Citation Analysis]
30 Lin H, Zhang X, Li G, Wong GL, Wong VW. Epidemiology and Clinical Outcomes of Metabolic (Dysfunction)-associated Fatty Liver Disease. J Clin Transl Hepatol 2021;9:972-82. [PMID: 34966660 DOI: 10.14218/JCTH.2021.00201] [Reference Citation Analysis]